CA2177721A1 - Taste masked composition containing a drug/polymer complex - Google Patents

Taste masked composition containing a drug/polymer complex

Info

Publication number
CA2177721A1
CA2177721A1 CA002177721A CA2177721A CA2177721A1 CA 2177721 A1 CA2177721 A1 CA 2177721A1 CA 002177721 A CA002177721 A CA 002177721A CA 2177721 A CA2177721 A CA 2177721A CA 2177721 A1 CA2177721 A1 CA 2177721A1
Authority
CA
Canada
Prior art keywords
chewable
taste masked
complex
therapeutic agent
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002177721A
Other languages
English (en)
French (fr)
Inventor
Franco Francese
Massimo Maneschi
Diego Oldani
Tiziana Crolla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline SpA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2177721A1 publication Critical patent/CA2177721A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6943—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a pill, a tablet, a lozenge or a capsule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002177721A 1993-12-03 1994-11-24 Taste masked composition containing a drug/polymer complex Abandoned CA2177721A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI93A002540 1993-12-03
ITMI932540A IT1274241B (it) 1993-12-03 1993-12-03 Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono

Publications (1)

Publication Number Publication Date
CA2177721A1 true CA2177721A1 (en) 1995-06-08

Family

ID=11367288

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002177721A Abandoned CA2177721A1 (en) 1993-12-03 1994-11-24 Taste masked composition containing a drug/polymer complex

Country Status (9)

Country Link
EP (1) EP0804168A1 (it)
JP (1) JPH09505818A (it)
CN (1) CN1145586A (it)
AU (1) AU693144B2 (it)
CA (1) CA2177721A1 (it)
IT (1) IT1274241B (it)
NZ (1) NZ277238A (it)
WO (1) WO1995015155A1 (it)
ZA (1) ZA949567B (it)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
AU748804B2 (en) * 1995-07-20 2002-06-13 Smithkline Beecham Plc Paroxetine controlled release compositions
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride
US5965555A (en) * 1996-06-07 1999-10-12 Hoechst Aktiengesellschaft Xanthine compounds having terminally animated alkynol side chains
DE19631084A1 (de) 1996-08-01 1998-02-05 Basf Ag Verwendung von (Meth)acrylsäure-Copolymeren zur Erhöhung der Permeabilität der Schleimhaut
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
EE03970B1 (et) 1997-06-10 2003-02-17 Synthon B.V. 4-fenüülpiperidiinühend, selle valmistamine ja kasutamine ning seda sisaldav ravim
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
BR9813808A (pt) * 1997-12-19 2002-05-28 Smithkline Beecham Corp Processo para produção de comprimidos para dispersão na mordida
IT1298732B1 (it) * 1998-03-13 2000-02-02 Recordati Chem Pharm Composizioni farmaceutiche orali assumibili senza liquidi,contenenti complessi di inclusione
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ATE311883T1 (de) 1999-03-12 2005-12-15 Aesica Pharmaceuticals Ltd Stabile pharmazeutische anwendungsform für paroxetin-anhydrat
WO2003013470A1 (en) * 2001-08-09 2003-02-20 Smithkline Beecham Plc. Composition comprising paroxetine and a pharmaceutically acceptable glycyrrhizinate salt
GB0119467D0 (en) * 2001-08-09 2001-10-03 Smithkline Beecham Plc Novel compound
PT2802311T (pt) * 2011-10-25 2019-03-19 Expermed S A Composição farmacêutica sublingual contendo um agente anti-histamínico e método para a sua preparação

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT83241B (pt) * 1985-08-26 1988-07-01 Searle & Co Processo para a preparacao de composicoes de drogas de matriz polimerica, capazes de mascarar o sabor de um ingrediente activo, contendo um polimero tendo uma serie de grupos acido e ester carboxilicos

Also Published As

Publication number Publication date
AU1219895A (en) 1995-06-19
WO1995015155A1 (en) 1995-06-08
EP0804168A1 (en) 1997-11-05
NZ277238A (en) 1998-04-27
CN1145586A (zh) 1997-03-19
IT1274241B (it) 1997-07-15
AU693144B2 (en) 1998-06-25
ITMI932540A0 (it) 1993-12-03
JPH09505818A (ja) 1997-06-10
ITMI932540A1 (it) 1995-06-03
ZA949567B (en) 1995-10-10

Similar Documents

Publication Publication Date Title
CA1320192C (en) Pharmaceutical compositions
JP3536106B2 (ja) 製剤及びその製造方法
US6649187B2 (en) Use of polyalkylamine polymers in controlled release devices
AU693144B2 (en) Taste masked composition containing a drug/polymer complex
US8758779B2 (en) Pharmaceutical composition of duloxetine
CA1146545A (en) Pharmaceutical composition comprising bencyclane fumarate and cyclodextrin
DE69419281T2 (de) Geschmacksmaskierte feste Zubereitung und Verfahren zur Herstellung
CA2163111C (en) Process for the preparation of an oral solid dosage form containing diclofenac
US5968906A (en) Sucralfate preparations
AU739295B2 (en) Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation
KR100675081B1 (ko) 아세틸시스테인 함유 경구용 제제
CA2618187C (en) Novel resinate complex of s-clopidogrel and production method thereof
SK278519B6 (en) Water soluble inclusive complex of silybinine together with cyclodextrine, preparation method thereof and pharmaceutical composition contaning that complex
HU204997B (en) Process for producing carrier system suitable for ensuring controlled biological access to dihydropyridines, as well as new oral dosage form ensuring improved biological access
US5834492A (en) Water soluble orally effective iron chelator
WO1996002531A1 (en) Water soluble orally effective iron chelator
AU732785B2 (en) Process for the preparation of an oral solid dosage form containing diclofenac
GB1596166A (en) Pharmaceutical compositions
EP0535269A1 (en) Pharmaceutical compositions containing thiazolidinedione derivatives
Chawan Preparation and Evaluation of Inclusion Complexes of Water Insoluble Drugs
IE990009A1 (en) Taste-masked composition
MXPA00001385A (en) Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation

Legal Events

Date Code Title Description
FZDE Discontinued